After the company went public, it closely grasped the new opportunities in the market and industry, gathered the development of specialty pharmacies, expanded the circuit through the Internet+ drug distribution and retail model, accelerated the digital group transformation, improved the big health industry chain, and led the company to a new stage of high-quality development. While increasing connotative growth, the company is shifting to epitaxial expansion, developing the pharmaceutical industry through acquisitions and mergers of pharmaceutical companies, increasing core product resources, and downstream through a direct management+merger and acquisition+franchise expansion model, focusing on expanding the development strategy of specialty pharmacies across provinces and regions, achieving a rapid increase in market share throughout the country, and achieving continuous rapid growth in the company's scale and efficiency. The company is mainly engaged in the distribution and retail business of pharmaceuticals, biological products, medical devices and other products. The company's main products include Xiaojianzhong granules, Wuwei Anshen granules, Jiuwei Gantai capsules, pediatric pharyngeal flat granules, azithromycin granules, etc. Company honors: 3rd Vice President Unit of Hunan Pharmaceutical Industry Association, Vice President Unit of Hunan Pharmaceutical Industry Association, 3A Credit Rating Unit of Hunan Enterprise Evaluation Center, etc.
No Data
No Data